Navigation path

AntiMal

Malaria

Development of New Drugs for the Treatment of Malaria
Framework programme:
6
Call:
3
Project number:
LSHP-CT-2005-018834
EC contribution:
€ 17 750 000
Duration:
60 months
Type:
IP
Starting date:
1 December 2005

Keywords: Malaria; chemotherapy; drug development; drug discovery

Summary:

Leading groups of malaria researchers will integrate their expertise in malaria biology, chemotherapy and drug development to exploit new scientific and political opportunities to secure the development of a portfolio of viable novel antimalarial drugs. These new chemical entities will be commercially attractive to industrial partners and, through the generation of PPP’s, will result in affordable new antimalarial drugs registered to internationally recognised standards. The scientific programme of this IP will comprise complementary clusters of basic and applied scientific investigation, will build on the technology platforms generated by the BioMalPar NoE and will provide candidate molecules for clinical evaluation by the ‘European and Developing Countries Clinical Trials Partnership’ (EDCTP) programme. The IP will focus on the following areas: novel quinolines, novel peroxides, lipid targets, other targets and post candidate development. The project will bring together European research institutes of established international reputation in the field of malaria biology and chemotherapy, and their affiliated research groups in malaria-endemic areas. Through AntiMal’s programme of jointly executed research, 29 European research groups will support the network’s goals to generate viable lead drug molecules in collaboration with eight SMEs and four partners from malaria-endemic countries (including two SMEs). In addition to strengthening existing European excellence, increasing institutional integration and creating a durable structure of basic and applied malaria research in Europe with a focus on drugs, these activities will establish critical mass at the European level and integrate malaria specialists into a ‘virtual drug discovery and development’ structure with one focused scientific objective: the delivery of a new drug/s for malaria. The integration will provide international leadership, disseminate expertise and resources, provide training and mobility of scientists at all levels, and foster long-term collaborations that will strengthen European malaria research. A strong central management structure will be built around the core group of 33 institutions with contributions from 19 European countries, which will give opportunities for future participation from other EU and non-EU partners.

[+] Read More